InMode at Jefferies Conference: Navigating Economic Challenges

During the Jefferies Global Healthcare Conference 2025, InMode (INMD) reported Q1 2024 revenue below expectations, leading to a revised flat revenue outlook for the year and adjusted profitability guidance; the company's revenue mix is now evenly split between the U.S. and international markets, impacting profitability due to headwinds in the U.S. and tariffs on Israeli-manufactured products. InMode is restructuring its North American sales force and focusing on new product launches in women’s health, ophthalmology, urology, and ENT, with 15 R&D projects in the pipeline, while also actively pursuing acquisitions in the injectable business and having spent $508 million on stock buybacks over the past two years.

Analysis

InMode Ltd. is navigating a challenging macroeconomic environment, as highlighted during its presentation at the Jefferies Global Healthcare Conference 2025. The company reported Q1 2024 revenues below expectations, leading to a forecast of flat year-over-year revenue and a downward revision of its profitability guidance. This is attributed to significant headwinds in the U.S. market, where its contribution to revenue has fallen to 50%, now matching international markets—a shift negatively impacting overall profitability as the U.S. has historically been more lucrative. Furthermore, InMode is absorbing tariffs on its Israeli-manufactured products, which is further pressuring margins. Despite these difficulties, the company maintains a robust cash position of approximately half a billion dollars and has executed $508 million in stock buybacks over the past two years. Operationally, InMode has restructured its North American sales force, dividing the U.S. into East and West regions, and is testing specialized sales teams. Growth in Europe and Asia offers a positive contrast, with Europe delivering a record Q1. Future growth prospects are pinned on a substantial R&D pipeline featuring 15 projects, with plans to launch two new platforms annually, including a new erectile dysfunction platform anticipated by year-end 2025. InMode is also actively exploring M&A opportunities, particularly in the injectable sector, although recent acquisition proposals were not accepted. Sales of its Empower and Envision platforms declined by 20% in 2024, reflecting broader market softness for capital equipment and underscoring the importance of new product introductions.

Key Decisions for Investors

• Assess the impact of the U.S. sales force restructuring and ongoing tariff absorption on near-term profitability, while closely tracking the sustained growth momentum in European and Asian markets.
• Monitor the commercial launch and market adoption of the new erectile dysfunction platform expected by late 2025, and scrutinize the broader R&D pipeline's progress in delivering new revenue streams to offset recent sales declines in key existing platforms like Empower and Envision.
• Evaluate management's upcoming capital allocation decisions, specifically the strategic balance between pursuing M&A in the injectable business versus executing further share repurchases, considering the company's substantial cash reserves, shareholder feedback, and potential tax implications.
• Weigh InMode's long-term innovation potential, underpinned by its R&D initiatives and strong balance sheet, against the persistent macroeconomic headwinds and the inherent cyclicality of the aesthetics market when considering adjustments to investment positions.